Interleukin-12 receptor β2: From cytokine receptor to gatekeeper gene in human B-cell malignancies

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4809-4816

  Pistoia, Vito ^a   Cocco, Claudia ^a   Airoldi, Irma ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; CYTOKINE RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; IL12RB2 PROTEIN, HUMAN; IL12RB2 PROTEIN, MOUSE; INTERLEUKIN 12 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER STAGING; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOKINE PRODUCTION; DIARRHEA; DRUG DOSE COMPARISON; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; IMMUNE SYSTEM; KNOCKOUT MOUSE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; ONCOGENE; PANCYTOPENIA; PETECHIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VOMITING; ANIMAL; B CELL LYMPHOMA; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; MOUSE; MOUSE MUTANT; PATHOLOGY;

ANIMALS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-12;

EID: 70350439428     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.3579     Document Type: Review

References (60)

1. Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845, 1989
2. Stern AS, Podlaski FJ, Hulmes JD, et al: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 87:6808-6812, 1990
3. Macatonia SE, Hosken NA, Litton M, et al: Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154:5071-5079, 1995
4. Magram J, Connaughton SE, Warrier RR, et al: IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4:471-481, 1996
5. Manetti R, Gerosa F, Giudizi MG, et al: Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 179:1273-1283, 1994
6. Wolf SF, Temple PA, Kobayashi M, et al: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074-3081, 1991
7. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
8. Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168, 2002
9. Smyth MJ, Taniguchi M, Street SE: The antitumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J Immunol 165:2665-2670, 2000
10. Cole KE, Strick CA, Paradis TJ, et al: Interferon-inducible T cell alpha chemoattractant (ITAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009-2021, 1998
11. Kanegane C, Sgadari C, Kanegane H, et al: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64:384-392, 1998
12. Sgadari C, Farber JM, Angiolillo AL, et al: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89:2635-2643, 1997
13. Gillessen S, Carvajal D, Ling P, et al: Mouse interleukin-12 (IL-12) p40 homodimer: A potent IL-12 antagonist. Eur J Immunol 25:200-206, 1995
14. Presky DH, Yang H, Minetti LJ, et al: A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 93:14002-14007, 1996
15. Collison LW, Workman CJ, Kuo TT, et al: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569, 2007
16. Trinchieri G, Pflanz S, Kastelein RA: The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity 19:641-644, 2003
17. Airoldi I, Gri G, Marshall JD, et al: Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol 165:6880-6888, 2000
18. Bacon CM, Petricoin EF 3rd, Ortaldo JR, et al: Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A 92:7307-7311, 1995
19. Cho SS, Bacon CM, Sudarshan C, et al: Activation of STAT4 by IL-12 and IFN-alpha: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 157:4781-4789, 1996
20. Grohmann U, Belladonna ML, Bianchi R, et al: IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9:315-323, 1998
21. Kaplan MH, Sun YL, Hoey T, et al: Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174-177, 1996
22. Thierfelder WE, van Deursen JM, Yamamoto K, et al: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174, 1996
23. Wang KS, Frank DA, Ritz J: Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95:3183-3190, 2000
24. Airoldi I, Cocco C, Di Carlo E, et al: Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res 66:3978-3980, 2006
25. Airoldi I, Cocco C, Giuliani N, et al: Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112:750-759, 2008
26. Airoldi I, Di Carlo E, Banelli B, et al: The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 113: 1651-1659, 2004
27. Jelinek DF, Braaten JK: Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 154:1606-1613, 1995
28. Wu C, Wang X, Gadina M, et al: IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J Immunol 165: 6221-6228, 2000
29. Airoldi I, Di Carlo E, Cocco C, et al: Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106:3846-3853, 2005
30. Roodman GD: Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 17:1921-1925, 2002
31. Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol 4:557-564, 2003
32. Schafer ZT, Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 117:3660-3663, 2007
33. Kovalchuk AL, Kim JS, Park SS, et al: IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 99:1509-1514, 2002
34. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 36:69-86, 2000
35. Airoldi I, Guglielmino R, Carra G, et al: The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes. Haematologica 87:434-442, 2002
36. Razin A, Cedar H: DNA methylation and genomic imprinting. Cell 77:473-476, 1994
37. Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. Science 293:1089-1093, 2001
38. Baylin SB, Esteller M, Rountree MR, et al: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687-692, 2001
39. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
40. Fraga MF, Ballestar E, Villar-Garea A, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400, 2005
41. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
42. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
43. Cozen W, Gill PS, Salam MT, et al: Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood 111:3377-3382, 2008
44. Sorm F, Piskala A, Cihak A, et al: 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20:202-203, 1964
45. Lyko F, Brown R: DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97:1498-1506, 2005
46. Zhou L, Cheng X, Connolly BA, et al: Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321:591-599, 2002
47. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
48. Mund C, Hackanson B, Stresemann C, et al: Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65:7086-7090, 2005
49. Soriano AO, Yang H, Faderl S, et al: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308, 2007
50. Atkins MB, Robertson MJ, Gordon M, et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409-417, 1997
51. Heinzerling L, Burg G, Dummer R, et al: Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy. Hum Gene Ther 16:35-48, 2005
52. Kang WK, Park C, Yoon HL, et al: Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study. Hum Gene Ther 12:671-684, 2001
53. Robertson MJ, Cameron C, Atkins MB, et al: Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5:9-16, 1999
54. Salem ML, Gillanders WE, Kadima AN, et al: Review: Novel nonviral delivery approaches for interleukin-12 protein and gene systems-Curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 26:593-608, 2006
55. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640, 2004
56. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
57. Desai BB, Quinn PM, Wolitzky AG, et al: IL-12 receptor: II. Distribution and regulation of receptor expression. J Immunol 148:3125-3132, 1992
58. Szabo SJ, Dighe AS, Gubler U, et al: Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185:817-824, 1997
59. Soengas MS, Capodieci P, Polsky D, et al: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211, 2001
60. Halin C, Rondini S, Nilsson F, et al: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20:264-269, 2002